A 52-year-old man from Delhi presents to the pain clinic with chronic neuropathic pain in his lower limbs following a spinal cord injury 18 months ago. He reports burning pain, allodynia, and hyperalgesia. He has already tried gabapentin and pregabalin without adequate relief. On examination, he has intact motor function but diminished sensation below the level of injury. What is the most appropriate next step in management to target the underlying pain pathway dysfunction?

Explanation

## Clinical Context: Neuropathic Pain Management **Key Point:** Spinal cord stimulation (SCS) is indicated when pharmacological management of neuropathic pain has failed with at least two classes of first-line agents (gabapentinoids and SNRIs/TCAs). ### Pathophysiology of Post-SCI Neuropathic Pain The patient's burning pain, allodynia, and hyperalgesia reflect central sensitization and aberrant processing in the dorsal horn of the spinal cord. This involves: - Loss of inhibitory GABAergic and glycinergic interneurons - Upregulation of excitatory neurotransmitters (glutamate, substance P) - Activation of microglia and astrocytes - Altered gate control mechanism (see Melzack-Wall Gate Control Theory) ### Why SCS Is the Next Appropriate Step **High-Yield:** SCS works by activating large-diameter A-beta fibers in the dorsal columns, which suppress nociceptive transmission in the dorsal horn via the gate control mechanism. This is mechanistically different from pharmacological approaches and targets the underlying pathway dysfunction. **Clinical Pearl:** The patient has already failed two first-line pharmacological agents (gabapentin and pregabalin—both gabapentinoids). According to international neuropathic pain guidelines, when monotherapy or dual therapy with first-line agents fails, interventional modalities like SCS should be considered before escalating to opioids. ### Management Algorithm for Refractory Neuropathic Pain ```mermaid flowchart TD A[Neuropathic pain diagnosis]:::outcome --> B[First-line: Gabapentinoid or SNRI/TCA]:::action B --> C{Adequate relief?}:::decision C -->|Yes| D[Continue + optimize]:::action C -->|No| E[Add second agent from different class]:::action E --> F{Adequate relief?}:::decision F -->|Yes| G[Dual therapy maintenance]:::action F -->|No| H[Pharmacological failure]:::outcome H --> I{Candidate for SCS?}:::decision I -->|Yes| J[Refer for SCS evaluation]:::action I -->|No| K[Consider low-dose opioids + adjuvants]:::action J --> L[Trial stimulation, then implantation]:::action ``` **Mnemonic:** **SNAG** = Spinal Nerve, Allodynia, Gate control → **SCS** is the next step when drugs fail. ### Why Not the Other Options? | Option | Rationale for Rejection | |--------|------------------------| | Further pregabalin escalation | Patient has already failed gabapentinoids; increasing dose without adding a complementary agent (SNRI/TCA) delays progression to interventional therapy. | | Duloxetine + lidocaine patches | These are appropriate *before* considering SCS, not after dual pharmacological failure. The patient needs an interventional approach now. | | Morphine as first opioid | Opioids are reserved for refractory cases after exhausting non-opioid and interventional options. Early opioid use in neuropathic pain is associated with tolerance, dependence, and poor long-term outcomes. | **Warning:** Do not confuse SCS with other spinal procedures (e.g., intrathecal baclofen for spasticity, epidural steroid injection for radiculopathy). SCS is specifically for neuropathic pain via gate control modulation.